secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0001193125-22-086616
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phathom appoints Molly Henderson as CFO/Chief Business Officer; Guzzo to depart
-------------------------------------------------------------------------------

- Molly Henderson, former Urogen Pharma CFO, becomes Chief Financial and Business Officer effective April 5, 2022.
- Henderson's base salary $480,000; target bonus 45% of salary; receives options for 100k shares and 20k RSUs.
- Anthony Guzzo, Chief Accounting Officer and acting principal financial officer, to depart around Aug 15, 2022.
- Guzzo's departure not due to disagreement; vesting extended for certain PSVs and option exercise period to Dec 31, 2022.
- Henderson replaces Guzzo as principal financial and accounting officer effective April 5, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/0001193125-22-086616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/d306197d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-086616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer